Company · CIK 0001743881 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
BridgeBio Pharma, Inc. · BBIO
Insider activity reported against this company. All insider holders · Files at: EIDX. On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 SForm 4 → | Sep 21, 6:21 pm EDT | Neil KumarChief Executive Officer, Director | 10,000 | $69.08 | $690,847 | 495,686 | −1.98% | 10b5-1 |
| Aug 18, 2026 SForm 4 → | Aug 20, 4:31 pm EDT | Neil KumarChief Executive Officer, Director | 44,980 | $82.86 | $3,727,251 | 505,686 | −8.17% | 10b5-1 |
| Aug 16, 2026 FForm 4 → | Aug 18, 6:02 pm EDT | Thomas TrimarchiPresident and CFO | 22,781 | $79.86 | $1,819,291 | 336,529 | — | |
| Aug 16, 2026 FMForm 4 → | Aug 18, 6:02 pm EDT | Neil KumarChief Executive Officer, Director | 107,454 | $79.86 | $2,893,887 | 278,307 | — | |
| Aug 16, 2026 FForm 4 → | Aug 18, 6:02 pm EDT | Maricel ApuliChief Accounting Officer | 4,714 | $79.86 | $376,460 | 122,687 | — | |
| Jul 30, 2026 SForm 4 → | Aug 3, 4:20 pm EDT | Maricel ApuliChief Accounting Officer | 2,000 | $80.06 | $160,120 | 127,401 | −1.55% | 10b5-1 |
| Jul 9, 2026 SForm 4 → | Jul 13, 4:41 pm EDT | Andrea EllisDirector | 17,167 | $84.00 | $1,442,028 | 22,579 | −43.2% | 10b5-1 |
| Jul 9, 2026 MForm 4 → | Jul 13, 4:41 pm EDT | Andrea EllisDirector | 17,167 | $16.75 | $287,547 | 39,746 | — | 10b5-1 |
| Jul 9, 2026 SForm 4 → | Jul 13, 4:40 pm EDT | Jennifer E. CookDirector | 148,589 | $88.54 | $13,156,008 | 8,383 | −94.7% | 10b5-1 |
| Jul 9, 2026 MForm 4 → | Jul 13, 4:40 pm EDT | Jennifer E. CookDirector | 148,589 | $24.96 | $3,708,335 | 156,972 | — | 10b5-1 |
| Jun 23, 2026 SForm 4 → | Jun 24, 6:06 pm EDT | Jennifer E. CookDirector | 39,363 | $69.92 | $2,752,270 | 8,383 | −82.4% | 10b5-1 |
| Jun 22, 2026 AMForm 4 → | Jun 24, 6:06 pm EDT | Jennifer E. CookDirector | 41,157 | $12.28 | $456,547 | 45,550 | — | 10b5-1 |
| Jun 22, 2026 SForm 4 → | Jun 24, 6:06 pm EDT | Hannah ValantineDirector | 5,004 | $68.25 | $341,524 | 9,259 | −35.1% | 10b5-1 |
| Jun 22, 2026 AMForm 4 → | Jun 24, 6:06 pm EDT | Hannah ValantineDirector | 6,798 | $41.73 | $117,178 | 14,263 | — | 10b5-1 |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:06 pm EDT | Andrew LoDirector | 3,990 | — | — | 18,079 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:06 pm EDT | Charles J HomcyDirector | 3,990 | — | — | 919,876 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:06 pm EDT | Eric AguiarDirector | 3,990 | — | — | 10,579 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:05 pm EDT | Ronald J DanielsDirector | 3,990 | — | — | 20,981 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:05 pm EDT | Andrea EllisDirector | 3,990 | — | — | 22,579 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:05 pm EDT | Fred HassanDirector | 3,990 | — | — | 29,879 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:05 pm EDT | James C MomtazeeDirector | 3,990 | — | — | 19,070 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:05 pm EDT | Frank McCormickDirector | 3,990 | — | — | 10,579 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:05 pm EDT | Douglas A. DachilleDirector | 3,990 | — | — | 10,579 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:05 pm EDT | Ali J. SatvatDirector | 3,990 | — | — | 169,983 | — | |
| Jun 20, 2026 FForm 4 → | Jun 23, 6:46 pm EDT | Charles J HomcyDirector | 788 | $66.27 | $52,221 | 915,886 | — | |
| Jun 15, 2026 SForm 4 → | Jun 17, 4:45 pm EDT | Jennifer E. CookDirector | 90,240 | $66.62 | $6,012,157 | 6,589 | −93.2% | 10b5-1 |
| Jun 15, 2026 MForm 4 → | Jun 17, 4:45 pm EDT | Jennifer E. CookDirector | 83,088 | $10.16 | $844,580 | 96,829 | — | 10b5-1 |
| Jun 4, 2026 SForm 4 → | Jun 8, 6:01 pm EDT | Neil KumarChief Executive Officer, Director | 80,000 | $67.67 | $5,413,289 | 4,318,447 | −1.82% | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2026 MForm 4 → | Aug 18, 6:02 pm EDT | Neil KumarChief Executive Officer, Director | 71,217 | — | — | 91,274 | — | |
| Jul 9, 2026 MForm 4 → | Jul 13, 4:41 pm EDT | Andrea EllisDirector | 17,167 | — | — | 17,167 | — | 10b5-1 |
| Jul 9, 2026 MForm 4 → | Jul 13, 4:40 pm EDT | Jennifer E. CookDirector | 148,589 | — | — | 0 | — | 10b5-1 |
| Jun 22, 2026 AMForm 4 → | Jun 24, 6:06 pm EDT | Jennifer E. CookDirector | 42,444 | — | — | 17,167 | — | 10b5-1 |
| Jun 22, 2026 AMForm 4 → | Jun 24, 6:06 pm EDT | Hannah ValantineDirector | 8,085 | — | — | 5,617 | — | 10b5-1 |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:06 pm EDT | Andrew LoDirector | 5,277 | — | — | 5,277 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:06 pm EDT | Charles J HomcyDirector | 5,277 | — | — | 5,277 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:06 pm EDT | Eric AguiarDirector | 5,277 | — | — | 5,277 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:05 pm EDT | Ronald J DanielsDirector | 5,277 | — | — | 5,277 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:05 pm EDT | Andrea EllisDirector | 5,277 | — | — | 5,277 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:05 pm EDT | Fred HassanDirector | 5,277 | — | — | 5,277 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:05 pm EDT | James C MomtazeeDirector | 5,277 | — | — | 5,277 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:05 pm EDT | Frank McCormickDirector | 5,277 | — | — | 5,277 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:05 pm EDT | Douglas A. DachilleDirector | 5,277 | — | — | 5,277 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 6:05 pm EDT | Ali J. SatvatDirector | 5,277 | — | — | 5,277 | — | |
| Jun 15, 2026 MForm 4 → | Jun 17, 4:45 pm EDT | Jennifer E. CookDirector | 83,088 | — | — | 34,334 | — | 10b5-1 |
Filed by this entity as an insider elsewhere — common stock
| Trade | Reported (ET) | Company | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 10, 2018 PForm 4/A → | Dec 13, 6:14 pm EST | Eidos Therapeutics, Inc.EIDX | 40,653 | $13.33 | $542,063 | 22,589,300 | +0.18% | plan? |
| Dec 10, 2018 SForm 4 → | Dec 12, 5:44 pm EST | Eidos Therapeutics, Inc.EIDX | 40,653 | $13.33 | $542,063 | 22,589,300 | — | plan? amended |
| Dec 6, 2018 PForm 4/A → | Dec 13, 6:13 pm EST | Eidos Therapeutics, Inc.EIDX | 80,144 | $13.67 | $1,095,867 | 22,548,647 | +0.36% | plan? |
| Dec 6, 2018 SForm 4 → | Dec 10, 7:25 pm EST | Eidos Therapeutics, Inc.EIDX | 80,144 | $13.67 | $1,095,867 | 22,548,647 | — | plan? amended |
| Dec 3, 2018 PForm 4 → | Dec 6, 8:48 pm EST | Eidos Therapeutics, Inc.EIDX | 2,853,848 | $14.92 | $42,589,910 | 22,468,503 | +14.5% | plan? |
| Jun 22, 2018 PForm 4 → | Jun 26, 4:30 pm EDT | Eidos Therapeutics, Inc.EIDX | 1,000,000 | $17.00 | $17,000,000 | 19,614,655 | +5.37% | plan? |
| Jun 22, 2018 CFForm 4 → | Jun 26, 4:30 pm EDT | Eidos Therapeutics, Inc.EIDX | 19,038,179 | $17.00 | $3,599,954 | 18,614,655 | — | plan? |
Filed by this entity as an insider elsewhere — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Company | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 22, 2018 CXForm 4 → | Jun 26, 4:30 pm EDT | Eidos Therapeutics, Inc.EIDX | 16,405,676 | — | — | 0 | — |